Topiramate in migraine prophylaxis

D. D'Amico, L. Grazzi, S. Usai, F. Moschiano, G. Bussone

Research output: Contribution to journalArticlepeer-review


This paper reviews results of placebo-controlled trials on topiramate (TPM) prophylaxis in migraine patients, and discusses issues regarding the use of this medication in clinical practice. Data from well conducted double-blind controlled trials and from a comparative trial show that TPM is effective against migraine, confirming the experience of physicians in various countries. Lack of major contraindications, high responder rate, good tolerability at the target dose (100 mg/day) following slow titration, and lack of weight gain make TPM one of the most effective and well accepted drugs for migraine prophylaxis.

Original languageEnglish
JournalNeurological Sciences
Issue numberSUPPL. 2
Publication statusPublished - May 2005


  • Clinical practice
  • Clinical trial
  • Migraine
  • Prophylaxis
  • Topiramate

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Topiramate in migraine prophylaxis'. Together they form a unique fingerprint.

Cite this